Skip to content
CACA·WikiThe living current-affairs record
--:--:--to drop
Sign in
Science & Technologyv2 · 2 versions

Indian Biotech Breakthroughs

India's biotech story in 2025-26 is a set of home-grown firsts at very different stages of ripeness, and the exam-smart move is to know exactly how far each has travelled. NexCAR19, a made-in-India CAR-T cancer therapy, is already treating patients; BIRSA 101, an indigenous CRISPR fix for sickle cell disease, has been unveiled and handed to industry; AdFalciVax, a home-grown malaria vaccine, is still an early candidate; and SKUAST-Kashmir has produced the country's first gene-edited sheep. August 2026 added three laboratory results from Department of Science and Technology institutes: RK-251, a cancer prodrug that switches on only inside tumour cells; TZ-48, a fluorescent probe paired with a smartphone app to read Alzheimer's biomarkers; and SAMBAR, the first baseline map of healthy South Asian gut microbiomes.

Last updated 27 August 20268 min read
Latest update
Added three August 2026 lab results from DST institutes: RK-251, a prodrug that activates only inside tumour cells (IASST and IIT Guwahati); TZ-48 with the ADxFluor phone app for reading Alzheimer's amyloid in blood (JNCASR); and SAMBAR, the 575-person South Asian gut-microbiome baseline (BSIP). Restructured the capsule for faster reading; no earlier fact removed.

Read the full living note — free

The complete note in both exam lenses (UPSC analytical / fact capsule), its full version history, and “what changed since you last read” — plus tonight's quiz.

Open in CA·Wiki

AI-assisted, human-reviewed · sourced from PIB, RBI & ministries · editorial policy

More living notes in Science & Technology

Browse all topics →

Indian Biotech Breakthroughs — Science & Technology current affairs | CA·Wiki